TC
CTMX icon

Truvestments Capital’s CytomX Therapeutics CTMX Stock Holding History

Truvestments Capital’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$105K Buy
27,988
+560
+2% +$2.14K 0.02% 395
2026
Q1 		$129K Hold
27,428
– – 0.02% 344
2025
Q4 		$117K Buy
27,428
+10,327
+60% +$39.2K 0.02% 317
2025
Q3 		$54.6K Buy
17,101
+2,233
+15% +$5.03K 0.01% 423
2025
Q2 		$33.8K Buy
+14,868
New +$24K 0.01% 464

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Truvestments Capital's CTMX Position: Q2 2026 in Review

Truvestments Capital increased its CytomX Therapeutics (CTMX) stake by 2% in Q2 2026, buying an estimated $2.14K and bringing the position to 27,988 shares worth $105K. The position accounts for 0.02% of the portfolio, ranked #395.

Truvestments Capital first reported a position in CTMX in Q2 2025 and has held it in 5 quarters since. The position peaked at $129K in Q1 2026. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Truvestments Capital held 27,988 shares of CytomX Therapeutics worth $105K as of Q2 2026.
  • Truvestments Capital bought 560 CytomX Therapeutics shares in Q2 2026, an estimated $2.14K.
  • CytomX Therapeutics made up 0.02% of Truvestments Capital's portfolio in Q2 2026, its #395 holding.
  • Truvestments Capital first reported a position in CytomX Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Truvestments Capital's CytomX Therapeutics position peaked at $129K in Q1 2026.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.